BioCentury | Oct 26, 2018
Product Development

R&D merry-go-round

...a physician at the Dana-Farber Cancer Institute. He also brought entrepreneurial experience as co-founder of Acetylon Pharmaceuticals Inc....
BioCentury | Apr 13, 2018
Emerging Company Profile

Reversing Neuropathy

...first disease-modifying therapy for chemotherapy-induced peripheral neuropathy and diabetic neuropathy. Regenacy was spun out of Acetylon Pharmaceuticals Inc....
...indications. Celgene has ricolinostat in Phase I/II trials to treat lymphoma and multiple myeloma (MM). Acetylon...
...data from a Phase I trial of the compound in patients with MM conducted by Acetylon...
BioCentury | Jan 27, 2018
Strategy

Jump-starting growth

...Citarinostat (ACY-241) Oral histone deacetylase 6 (HDAC6) inhibitor MM, melanoma, NSCLC, solid tumors (Ph I) Acetylon Pharmaceuticals Inc....
BioCentury | Sep 21, 2017
Tools & Techniques

On your marks

...understanding of the biology of each different protein,” said Morrison. Regenacy was spun out of Acetylon Pharmaceuticals Inc....
BioCentury | Jul 5, 2017
Company News

Management tracks

...EPIX Pharmaceuticals Inc. (Pink:EPIX). Jones succeeds Walter Ogier, who will remain a director. Last December, Acetylon Pharmaceuticals Inc....
BioCentury | Feb 15, 2017
Distillery Therapeutics

Neurology

...syndrome (MDS) and non-Hodgkin’s lymphoma (NHL) and preclinical testing for non-small cell lung cancer (NSCLC). Acetylon Pharmaceuticals Inc....
BioCentury | Dec 9, 2016
Company News

Acetylon, Celgene deal

...Acetylon said Celgene will acquire it for undisclosed terms. Prior to the deal's completion, Acetylon will...
...deacetylase (HDAC) assets into newco Regenacy Pharmaceuticals LLC (Boston, Mass.). Celgene will gain rights to Acetylon's...
...financial terms. Acetylon Pharmaceuticals Inc. , Boston, Mass. Celgene Corp. (NASDAQ:CELG), Summit, N.J. Business: Cancer, Neurology, Autoimmune Alicia Parker ACY-1215 ACY-241 citarinostat ricolinostat Acetylon Pharmaceuticals Inc. Celgene...
BioCentury | Dec 3, 2016
Company News

Celgene acquiring Acetylon after spinout of newco

...said Celgene Corp. (NASDAQ:CELG) will acquire it for undisclosed terms. Prior to the deal's completion, Acetylon...
...to acquire Acetylon under a 2013 deal, but allowed the option to expire in May. Acetylon...
...an equity stake in Acetylon after the option expired (see BioCentury Extra, Aug. 8) . Acetylon...
BioCentury | Aug 15, 2016
Company News

Acetylon, Celgene deal

...Celgene revealed in a regulatory filing that it did not exercise its option to acquire Acetylon...
...expire in May. It paid $100 million up front to acquire the option in 2013. Acetylon...
...and lymphoma. Celgene still holds an equity stake in Acetylon (see BioCentury, Aug 5, 2013). Acetylon Pharmaceuticals Inc....
BioCentury | Aug 8, 2016
Company News

Celgene declines Acetylon option

...NASDAQ:CELG) revealed in a regulatory filing that it did not exercise its option to acquire Acetylon Pharmaceuticals Inc....
...in 2013 (see BioCentury Extra, July 29, 2013) . If Celgene had exercised the option, Acetylon...
...have received at least $500 million and been eligible for another $1.1 billion in milestones. Acetylon...
Items per page:
1 - 10 of 64
BioCentury | Oct 26, 2018
Product Development

R&D merry-go-round

...a physician at the Dana-Farber Cancer Institute. He also brought entrepreneurial experience as co-founder of Acetylon Pharmaceuticals Inc....
BioCentury | Apr 13, 2018
Emerging Company Profile

Reversing Neuropathy

...first disease-modifying therapy for chemotherapy-induced peripheral neuropathy and diabetic neuropathy. Regenacy was spun out of Acetylon Pharmaceuticals Inc....
...indications. Celgene has ricolinostat in Phase I/II trials to treat lymphoma and multiple myeloma (MM). Acetylon...
...data from a Phase I trial of the compound in patients with MM conducted by Acetylon...
BioCentury | Jan 27, 2018
Strategy

Jump-starting growth

...Citarinostat (ACY-241) Oral histone deacetylase 6 (HDAC6) inhibitor MM, melanoma, NSCLC, solid tumors (Ph I) Acetylon Pharmaceuticals Inc....
BioCentury | Sep 21, 2017
Tools & Techniques

On your marks

...understanding of the biology of each different protein,” said Morrison. Regenacy was spun out of Acetylon Pharmaceuticals Inc....
BioCentury | Jul 5, 2017
Company News

Management tracks

...EPIX Pharmaceuticals Inc. (Pink:EPIX). Jones succeeds Walter Ogier, who will remain a director. Last December, Acetylon Pharmaceuticals Inc....
BioCentury | Feb 15, 2017
Distillery Therapeutics

Neurology

...syndrome (MDS) and non-Hodgkin’s lymphoma (NHL) and preclinical testing for non-small cell lung cancer (NSCLC). Acetylon Pharmaceuticals Inc....
BioCentury | Dec 9, 2016
Company News

Acetylon, Celgene deal

...Acetylon said Celgene will acquire it for undisclosed terms. Prior to the deal's completion, Acetylon will...
...deacetylase (HDAC) assets into newco Regenacy Pharmaceuticals LLC (Boston, Mass.). Celgene will gain rights to Acetylon's...
...financial terms. Acetylon Pharmaceuticals Inc. , Boston, Mass. Celgene Corp. (NASDAQ:CELG), Summit, N.J. Business: Cancer, Neurology, Autoimmune Alicia Parker ACY-1215 ACY-241 citarinostat ricolinostat Acetylon Pharmaceuticals Inc. Celgene...
BioCentury | Dec 3, 2016
Company News

Celgene acquiring Acetylon after spinout of newco

...said Celgene Corp. (NASDAQ:CELG) will acquire it for undisclosed terms. Prior to the deal's completion, Acetylon...
...to acquire Acetylon under a 2013 deal, but allowed the option to expire in May. Acetylon...
...an equity stake in Acetylon after the option expired (see BioCentury Extra, Aug. 8) . Acetylon...
BioCentury | Aug 15, 2016
Company News

Acetylon, Celgene deal

...Celgene revealed in a regulatory filing that it did not exercise its option to acquire Acetylon...
...expire in May. It paid $100 million up front to acquire the option in 2013. Acetylon...
...and lymphoma. Celgene still holds an equity stake in Acetylon (see BioCentury, Aug 5, 2013). Acetylon Pharmaceuticals Inc....
BioCentury | Aug 8, 2016
Company News

Celgene declines Acetylon option

...NASDAQ:CELG) revealed in a regulatory filing that it did not exercise its option to acquire Acetylon Pharmaceuticals Inc....
...in 2013 (see BioCentury Extra, July 29, 2013) . If Celgene had exercised the option, Acetylon...
...have received at least $500 million and been eligible for another $1.1 billion in milestones. Acetylon...
Items per page:
1 - 10 of 64